The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
Changhua site meets international regulatory standards for global medical applications
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Sun Pharma gets 8 observations from USFDA for Halol facility
Subscribe To Our Newsletter & Stay Updated
